Bravo for PRAVO

Abstract

Two decades ago, amidst predictions that novel molecularly targeted cancer therapies would sweep away the old treatments, many believed that radiotherapy was living on borrowed time. Regrettably, the optimism surrounding targeted therapies has now been tempered by knowledge that, apart from notable exceptions like imatinib in gastrointestinal stromal tumour, most new agents achieve only modest, short-term responses followed by rapid emergence of drug resistance.